bevacizumab + oxaliplatin + irinotecan + capecitabine

This combination chemotherapy and targeted therapy regimen is being evaluated as a first-line treatment for unresectable advanced colorectal cancer. The regimen utilizes an alternating biweekly schedule of bevacizumab combined with either XELOX (capecitabine and oxaliplatin) or XELIRI (capecitabine and irinotecan). Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and tumor growth. The chemotherapy components include oxaliplatin, a platinum-based small molecule that acts as a DNA alkylator to induce cross-linking; irinotecan, a small molecule topoisomerase I inhibitor that prevents DNA religation; and capecitabine, an oral fluoropyrimidine carbamate that is enzymatically converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase. This alternating strategy, studied by the Jiangsu Cancer Institute & Hospital, aims to potentially delay the onset of drug resistance in patients with metastatic colorectal cancer.

Other names

bevacizumab + biweekly XELOX/XELIRIbevacizumab + XELOX/XELIRI alternative regimenbevacizumab + oxaliplatin + irinotecan + capecitabine-Jiangsu Cancer Institute & Hospital-colorectal cancer